OTCMKTS:HLOSF Healios K.K. (HLOSF) Stock Price, News & Analysis $1.94 0.00 (0.00%) As of 03/12/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest About Healios K.K. Stock (OTCMKTS:HLOSF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Healios K.K. alerts:Sign Up Key Stats Today's Range$1.94▼$1.9450-Day Range$0.96▼$2.4252-Week Range$0.93▼$2.42VolumeN/AAverage Volume2,275 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHealios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.Read More… Remove Ads Healios K.K. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreHLOSF MarketRank™: Healios K.K. scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Healios K.K.. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Healios K.K. is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Healios K.K. is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Healios K.K.'s valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverHealios K.K. has a short interest ratio ("days to cover") of 201, which indicates bearish sentiment.Change versus previous monthShort interest in Healios K.K. has recently increased by 136.47%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHealios K.K. does not currently pay a dividend.Dividend GrowthHealios K.K. does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverHealios K.K. has a short interest ratio ("days to cover") of 201, which indicates bearish sentiment.Change versus previous monthShort interest in Healios K.K. has recently increased by 136.47%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Healios K.K. to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Healios K.K. insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 20.34% of the stock of Healios K.K. is held by institutions.Read more about Healios K.K.'s insider trading history. Receive HLOSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Healios K.K. and its competitors with MarketBeat's FREE daily newsletter. Email Address HLOSF Stock News HeadlinesHealios K.K. Announces FY2024 Financial Results Amid Strategic Focus on Regenerative MedicineFebruary 13, 2025 | tipranks.comHealios K.K. Partners with Akatsuki Therapeutics to Advance eNK Cell Therapy DevelopmentJanuary 20, 2025 | tipranks.comAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.March 13, 2025 | Altimetry (Ad)Healios Partners with AND Medical for Regenerative Medicine AdvancementsJanuary 17, 2025 | tipranks.comHealios Advances MultiStem Approval for ARDS in JapanJanuary 15, 2025 | tipranks.comHealios Ends Collaboration Talks with Nobelpharma on ARDS TherapyJanuary 15, 2025 | tipranks.comHealios Expands ProcellCure’s Capabilities with CDMO RoleJanuary 10, 2025 | tipranks.comHealios Appoints D.J. Skelton as Advisor to Bolster U.S. Drug DevelopmentJanuary 6, 2025 | tipranks.comSee More Headlines HLOSF Stock Analysis - Frequently Asked Questions How have HLOSF shares performed this year? Healios K.K.'s stock was trading at $1.35 on January 1st, 2025. Since then, HLOSF shares have increased by 43.7% and is now trading at $1.94. View the best growth stocks for 2025 here. How do I buy shares of Healios K.K.? Shares of HLOSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today3/13/2025Next Earnings (Estimated)5/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:HLOSF CIKN/A Webhealios.co.jp Phone81357778308FaxN/AEmployees64Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (OTCMKTS:HLOSF) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Healios K.K. Please log in to your account or sign up in order to add this asset to your watchlist. Share Healios K.K. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.